A disconnection between hsCRP, ALT and histological benefit was observed in the recent phase 2 CENTAUR trial of the CCR2/CCR5 antagonist cenicriviroc for treatment of NASH. Here, CCR5 is linked to metabolic dysfunction-associated steatohepatitis.